The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

A porous separator for a lithium-containing electrochemical cell is provided herein. The porous separator includes a porous substrate and an active layer comprising lithium ion-exchanged zeolite particles. Methods of manufacturing the porous separator and lithium-containing electrochemical cells including the porous separator are also provided herein.

A porous separator for a lithium-containing electrochemical cell is provided herein. The porous separator includes a porous substrate and an active layer comprising lithium ion-exchanged zeolite particles. Methods of manufacturing the porous separator and lithium-containing electrochemical cells including the porous separator are also provided herein.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to novel microporous zirconium silicate compositions that are formulated to remove toxins, e.g. potassium ions, from the gastrointestinal tract at an elevated rate without causing undesirable side effects. The preferred formulations are designed avoid increase in pH of urine in patients and/or avoid potential entry of particles into the bloodstream of the patient. Also disclosed is a method for preparing high purity crystals of UZSi-9 exhibiting an enhanced level of potassium exchange capacity. These compositions are particularly useful in the therapeutic treatment of hyperkalemia.

The present invention relates to a process for the preparation of a zeolitic material having a CHA-type framework structure comprising YO.sub.2 and X.sub.2O.sub.3, wherein said process comprises the steps of: (1) providing a mixture comprising one or more sources for YO.sub.2, one or more sources for X.sub.2O.sub.3, one or more tetraalkylammonium cation R.sup.1R.sup.2R.sup.3R.sup.4N.sup.+-containing compounds, and one or more tetraalkylammonium cation R.sup.5R.sup.6R.sup.7R.sup.8N.sup.+-containing compounds as structure directing agent; (2) crystallizing the mixture obtained in step (1) for obtaining a zeolitic material having a CHA-type framework structure; wherein Y is a tetravalent element and X is a trivalent element, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 independently from one another stand for alkyl, and wherein R.sup.8 stands for cycloalkyl, as well as to zeolitic materials which may be obtained according to the inventive process and to their use.

The present invention relates to a process for the preparation of a zeolitic material having a CHA-type framework structure comprising YO.sub.2 and X.sub.2O.sub.3, wherein said process comprises the steps of: (1) providing a mixture comprising one or more sources for YO.sub.2, one or more sources for X.sub.2O.sub.3, one or more tetraalkylammonium cation R.sup.1R.sup.2R.sup.3R.sup.4N.sup.+-containing compounds, and one or more tetraalkylammonium cation R.sup.5R.sup.6R.sup.7R.sup.8N.sup.+-containing compounds as structure directing agent; (2) crystallizing the mixture obtained in step (1) for obtaining a zeolitic material having a CHA-type framework structure; wherein Y is a tetravalent element and X is a trivalent element, wherein R.sup.1, R.sup.2, R.sup.3, R.sup.4, R.sup.5, R.sup.6, and R.sup.7 independently from one another stand for alkyl, and wherein R.sup.8 stands for cycloalkyl, as well as to zeolitic materials which may be obtained according to the inventive process and to their use.

The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.

The present invention relates to zirconium silicate compositions having a lead content that is below 0.6 ppm and methods of manufacturing zirconium silicate at reactor volumes exceeding 200-L with a lead content below 1.1 ppm. The lead content of the zirconium silicate of this invention are within the levels that are considered acceptable for extended use given the dose requirements for zirconium silicate.

Provided is a composite material including a plurality of porous silicate particles having a glass phase structure, a first active metal adsorbed into the glass phase structure of the porous silicate particles, and a modified layer containing a second active metal formed on the surfaces of the porous silicate particles. The porous silicate particles have an average pore diameter of from 3 nm to 50 nm, and the first active metal includes at least one of sodium, potassium, calcium, and magnesium.